Literature DB >> 24515615

Reinterpretation of the vibrational spectroscopy of the medicinal bioinorganic synthon c,c,t-[Pt(NH3)2Cl2(OH)2].

Timothy C Johnstone1, Stephen J Lippard.   

Abstract

The Pt(IV) complex c,c,t-[Pt(NH3)2Cl2(OH)2] is an important intermediate in the synthesis of Pt(IV) anticancer prodrugs and has been investigated as an anticancer agent in its own right. An analysis of the vibrational spectroscopy of this molecule was previously reported (Faggiani et al., Can. J. Chem. 60:529, 1982), in which crystallographic determination of the structure of the complex permitted a site group approach. The space group, however, was incorrectly assigned. In the present study we have redetermined at high resolution crystal structures of c,c,t-[Pt(NH3)2Cl2(OH)2] and c,c,t-[Pt(NH3)2Cl2(OH)2H2O2, which makes possible discussion of the effect of hydrogen bonding on the N-H and O-H vibrational bands. The correct crystallographic site symmetry of the platinum complex in the c,c,t-[Pt(NH3)2Cl2(OH)2] structure is used to conduct a new vibrational analysis using both group-theoretical and modern density functional theory methods. This analysis reveals the nature and symmetry of the "missing band" described in the original publication and suggests a possible explanation for its disappearance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515615      PMCID: PMC4031275          DOI: 10.1007/s00775-014-1109-6

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  8 in total

1.  Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes.

Authors:  Katie R Barnes; Alexander Kutikov; Stephen J Lippard
Journal:  Chem Biol       Date:  2004-04

2.  Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.

Authors:  Jenny Z Zhang; Ezequiel Wexselblatt; Trevor W Hambley; Dan Gibson
Journal:  Chem Commun (Camb)       Date:  2011-11-29       Impact factor: 6.222

Review 3.  Basis for design and development of platinum(IV) anticancer complexes.

Authors:  Matthew D Hall; Howard R Mellor; Richard Callaghan; Trevor W Hambley
Journal:  J Med Chem       Date:  2007-06-28       Impact factor: 7.446

4.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

5.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Authors:  C M Giandomenico; M J Abrams; B A Murrer; J F Vollano; M I Rheinheimer; S B Wyer; G E Bossard; J D Higgins
Journal:  Inorg Chem       Date:  1995-03       Impact factor: 5.165

6.  Platinum(IV) analogues of AMD473 (cis-[PtCl2(NH3)(2-picoline)]): preparative, structural, and electrochemical studies.

Authors:  Andrew R Battle; Robin Choi; David E Hibbs; Trevor W Hambley
Journal:  Inorg Chem       Date:  2006-08-07       Impact factor: 5.165

7.  Rapid biotransformation of satraplatin by human red blood cells in vitro.

Authors:  Jocelyn L Carr; Malcolm D Tingle; Mark J McKeage
Journal:  Cancer Chemother Pharmacol       Date:  2002-05-22       Impact factor: 3.333

8.  In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.

Authors:  Ulrike Olszewski; Florian Ach; Ernst Ulsperger; Gerhard Baumgartner; Robert Zeillinger; Patrick Bednarski; Gerhard Hamilton
Journal:  Met Based Drugs       Date:  2009-06-30
  8 in total
  4 in total

Review 1.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

2.  DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds.

Authors:  Meilin Mu; Hongwei Gao
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

3.  Comprehensive Vibrational Spectroscopic Investigation of trans,trans,trans-[Pt(N3)2(OH)2(py)2], a Pt(IV) Diazido Anticancer Prodrug Candidate.

Authors:  Robbin R Vernooij; Tanmaya Joshi; Evyenia Shaili; Manja Kubeil; Dominique R T Appadoo; Ekaterina I Izgorodina; Bim Graham; Peter J Sadler; Bayden R Wood; Leone Spiccia
Journal:  Inorg Chem       Date:  2016-06-03       Impact factor: 5.165

4.  Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment.

Authors:  Xiaoman Mao; Shuang Wu; Pilar Calero-Pérez; Ana P Candiota; Paula Alfonso; Jordi Bruna; Victor J Yuste; Julia Lorenzo; Fernando Novio; Daniel Ruiz-Molina
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.